Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection

Launched by IMPERIAL COLLEGE LONDON · Nov 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help locate a small growth called a pituitary adenoma in patients with Cushing's disease, a condition where the body produces too much cortisol, a hormone that helps manage stress and metabolism. The trial will use a special type of scan called a PET/CT scan with a dye called 11C-methionine, along with MRI scans, to improve the chances of finding the adenoma. If the adenoma is located, patients may be offered surgery to remove it, which can potentially cure the disease. If the adenoma cannot be found, participants will receive medication to help lower cortisol levels, and then undergo additional scans to see if the adenoma becomes clearer.

To be eligible for this study, participants must be at least 18 years old and either newly diagnosed with Cushing's disease without a clear target on their MRI or have previously had surgery for the same condition but still have high cortisol levels. It's important to note that some individuals may not be able to participate if they have specific health issues, are pregnant, or cannot attend scheduled visits. This trial aims to enhance the tools doctors use to find and treat Cushing's disease, ultimately leading to better outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• All participants must meet all of the following inclusion criteria:
• • age 18 years and older newly diagnosed with Cushing's disease and no/ an equivocal surgical target on MRI pituitary or
• • age 18 years and older and previously undergone pituitary surgery for Cushing's disease and clinical and biochemical evidence of persistent/ recurrent hypercortisolaemia and no/ an equivocal surgical target on MRI pituitary.
• Exclusion Criteria:
• Potential participants will be ineligible to enter the study if they meet any of the following exclusion criteria:
• • Absolute contraindication to osilodrostat therapy and/or 11C methionine PET.
• • Pregnancy or unwillingness to use secure contraception for the study duration (female participants only).
• • Unable to comply with study visit schedule.